Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Stock Information for Anebulo Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Anebulo Pharmaceuticals Inc.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
Sidoti Events, LLC's Virtual August Micro-Cap Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.